David Glass, MD, is a leader in skeletal muscle hypertrophy and atrophy research, a member of the National Academy of Sciences in the USA and delivered the 11th HyperMet talk on the 15.5.2025. His contributions include identifying IGF-1-AKT-mTORC1 activity as a major cause of skeletal muscle hypertrophy, linking FoxO transcription factors to muscle atrophy, and the identification of MuRF1 and Atrogin-1 as markers and mediators of muscle atrophy. He currently serves as Vice President of Research at Regeneron® Pharmaceuticals. Beyond his research, he is actively engaged in scientific methodology, proposing that it is better to base scientific research on research questions than on hypotheses. In his talk, he first introduced some of his major findings before presenting data on the effects of GLP-1-receptor agonists (e.g., semaglutide Wegovy) versus muscle hypertrophy-stimulating drugs versus the combination, confirming that stimulating muscle hypertrophy causes major fat loss while preserving muscle mass. He also presented data on skeletal muscle aging (sarcopenia), which is important for our ageing society as a major loss of muscle function results in a loss of independence and mobility. David Glass´s presentation demonstrated that he is not just a science manager but a leading scientist conducting clinically relevant skeletal muscle hypertrophy and atrophy research that shows substantial overlap with the work of our HyperMet research unit.